Michelle L. Dean

AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non-Small-Cell Lung Cancer.

An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: January 27, 2026

Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center Cohort.

Factors Associated With Long-Term Survivors With Epidermal Growth Factor Receptor Positive Non-Small Cell Lung Cancer Treated With First or Second-Generation Tyrosine Kinase Inhibitors: A Canadian Multi-Center Cohort.

Journal: Asia-Pacific journal of clinical oncology

Published: August 21, 2025

Analysis of a cancer-care based diagnosis program for lymphoma.

Analysis of a cancer-care based diagnosis program for lymphoma.

Journal: Leukemia & lymphoma

Published: March 26, 2025

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 31, 2024

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 03, 2024

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib.

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib.

Journal: Current oncology (Toronto, Ont.)

Published: March 28, 2024

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.

Journal: JAMA network open

Published: January 18, 2024

Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.

Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: September 05, 2023

Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer.

Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer.

Journal: Cancer genomics & proteomics

Published: January 04, 2023

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC.

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC.

Journal: JTO clinical and research reports

Published: November 28, 2022

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Journal: Current oncology (Toronto, Ont.)

Published: January 31, 2022

Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada.

Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada.

Journal: JTO clinical and research reports

Published: January 21, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026